130 related articles for article (PubMed ID: 37557922)
1. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.
Rezaei Z; Dastjerdi K; Allahyari A; ShahidSales S; Talebian S; Maharati A; Zangooie A; Zangouei AS; Sadri F; Sargazi S
Toxicol Appl Pharmacol; 2023 Sep; 475():116652. PubMed ID: 37557922
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.
Normann LS; Aure MR; Leivonen SK; Haugen MH; Hongisto V; Kristensen VN; Mælandsmo GM; Sahlberg KK
Sci Rep; 2021 May; 11(1):10893. PubMed ID: 34035375
[TBL] [Abstract][Full Text] [Related]
4. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669
[TBL] [Abstract][Full Text] [Related]
5. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
7. The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab.
Song W; Wu S; Wu Q; Zhou L; Yu L; Zhu B; Gong X
J Cell Biochem; 2019 Aug; 120(8):14095-14106. PubMed ID: 31087707
[TBL] [Abstract][Full Text] [Related]
8. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
Pizzamiglio S; Cosentino G; Ciniselli CM; De Cecco L; Cataldo A; Plantamura I; Triulzi T; El-Abed S; Wang Y; Bajji M; Nuciforo P; Huober J; Ellard SL; Rimm DL; Gombos A; Daidone MG; Verderio P; Tagliabue E; Di Cosimo S; Iorio MV
Cancer Med; 2022 Jan; 11(2):332-339. PubMed ID: 34921525
[TBL] [Abstract][Full Text] [Related]
9. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
[TBL] [Abstract][Full Text] [Related]
10. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
[TBL] [Abstract][Full Text] [Related]
11. Integrative bioinformatics analysis reveals miR-494 and its target genes as predictive biomarkers of trastuzumab-resistant breast cancer.
Hermawan A; Putri H
J Egypt Natl Canc Inst; 2020 Apr; 32(1):16. PubMed ID: 32372307
[TBL] [Abstract][Full Text] [Related]
12. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
Giray BG; Emekdas G; Tezcan S; Ulger M; Serin MS; Sezgin O; Altintas E; Tiftik EN
Mol Biol Rep; 2014 Jul; 41(7):4513-9. PubMed ID: 24595450
[TBL] [Abstract][Full Text] [Related]
13. Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers.
Jusoh AR; Mohan SV; Lu Ping T; Tengku Din TADAAB; Haron J; Romli RC; Jaafar H; Nafi SN; Tuan Salwani TI; Yahya MM
Asian Pac J Cancer Prev; 2021 May; 22(5):1375-1381. PubMed ID: 34048164
[TBL] [Abstract][Full Text] [Related]
14. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
15. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2
Decker JT; Hall MS; Blaisdell RB; Schwark K; Jeruss JS; Shea LD
Biotechnol Bioeng; 2018 Oct; 115(10):2613-2623. PubMed ID: 29981261
[TBL] [Abstract][Full Text] [Related]
16. Analysis of differential expression profile of miRNA in peripheral blood of patients with lung cancer.
He Q; Fang Y; Lu F; Pan J; Wang L; Gong W; Fei F; Cui J; Zhong J; Hu R; Liang M; Fang L; Wang H; Yu M; Zhang ZF
J Clin Lab Anal; 2019 Nov; 33(9):e23003. PubMed ID: 31541491
[TBL] [Abstract][Full Text] [Related]
17. Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
Noyan S; Gurdal H; Gur Dedeoglu B
PLoS One; 2019; 14(4):e0215894. PubMed ID: 31009516
[TBL] [Abstract][Full Text] [Related]
18. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
[TBL] [Abstract][Full Text] [Related]
19. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer.
Zhu XL; Ren LF; Wang HP; Bai ZT; Zhang L; Meng WB; Zhu KX; Ding FH; Miao L; Yan J; Wang YP; Liu YQ; Zhou WC; Li X
World J Gastroenterol; 2019 Apr; 25(13):1580-1591. PubMed ID: 30983818
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
